USP Octinoxate RS
[octyl methoxycinnamate
]
.
USP Octisalate RS
[octyl salicylate
]
.
USP Octocrylene RS
.
USP Octoxynol 9 RS
.
USP Octyldodecanol RS
.
USP Ofloxacin RS
.
USP Ofloxacin Related Compound A RS
[9-fluoro-3-methyl-7-oxo-10-(piperazin-1-yl)-2,3-dihydro-7
H-pyrido[1,2,3-
de]-1,4-benzoxazine-6-carboxylic acid
]
.
USP Oleoyl Polyoxylglycerides RS
.
Add the following:
USP Oleyl Oleate RS.
USP Omeprazole RS
.
Add the following:
USP Omeprazole Magnesium RS.
1S (USP31)
Add the following:
USP Omeprazole Related Compound A RS
[(omeprazole sulfone, 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]-1
H-benzimidazole)
]
(C
17H
19N
3O
4S
361.42
CAS-88546-55-8).
1S (USP31)
USP Ondansetron Hydrochloride RS
.
USP Ondansetron Related Compound A RS
[3[(dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4
H-carbazol-4-one
]
.
USP Ondansetron Related Compound B RS
[6,6
¢-methylene bis-[(1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1
H-imidazol-1-yl)-methyl]-4
H-carbazol-4-one
]
.
USP Ondansetron Related Compound C RS
[1,2,3,9-tetrahydro-9-methyl-4
H-carbazol-4-one
]
.
USP Ondansetron Related Compound D RS
[1,2,3,9-tetrahydro-9-methyl-3-methylene-4
H-carbazol-4-one
]
.
USP Ondansetron Resolution Mixture RS—
Ondansetron hydrochloride having approximately 0.4% w/w of both ondansetron related compound A and 6,6
¢-methylene bis-[(1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1
H-imidazol-1-yl)-methyl]-4
H-carbazol-4-one)].
USP Orphenadrine Citrate RS
.
USP Oxacillin Sodium RS
.
USP Oxandrolone RS
.
USP Oxandrolone Related Compound A RS
[(7,8-didehydro-oxandrolone) or (17
-hydroxy-17
-methyl-2-oxa-5
-androst-7-en-3-one)
].
USP Oxandrolone Related Compound B RS
[(anhydro-oxandrolone) or (17
-17-dimethyl-2-oxa-18-nor-5
-androstan-3-one)
].
USP Oxandrolone Related Compound C RS
[anhydro-oxandrolone (17,17-dimethyl-2-oxa-18-nor-5
-androstan-3-one)
]
.
USP Oxaprozin RS
.
USP Oxazepam RS
.
USP Oxfendazole RS
.
USP Oxprenolol Hydrochloride RS
.
USP Oxtriphylline RS
.
USP Oxybenzone RS
.
USP Oxybutynin Chloride RS
.
USP Oxybutynin Related Compound A RS [phenylcyclohexylglycolic acid]
(C
14H
18O
3
234.30)
.
USP Oxybutynin Related Compound B RS
[methyl ester of phenylcyclohexylglycolic acid, or CHMME (cyclohexyl mandelic acid methyl ester)
]
.
USP Oxybutynin Related Compound C RS
[methylethyl analog of oxybutynin chloride, or (4-(ethylmethylamino) but-2-ynyl (±) 2-cyclohexyl-2-hydroxy-2-phenylacetate hydrochloride)
]
.
USP Oxycodone RS
.
USP Oxygen–Helium RS.
USP Oxymetazoline Hydrochloride RS
.
USP Oxymetholone RS
.
USP Oxymorphone RS
.
USP Oxyquinoline Sulfate RS
.
USP Oxytetracycline RS
.
USP Oxytocin RS
.
;)
[octyl methoxycinnamate]
.
;)
[octyl salicylate]
.
;)
.
;)
.
;)
.
;)
.
;)
[9-fluoro-3-methyl-7-oxo-10-(piperazin-1-yl)-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid]
.
USP Oleic Acid RS.
;)
;)
;)
.
;)
.
;)
[3[(dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one]
.
;)
[6,6¢-methylene bis-[(1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one]
.
;)
[1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one]
.
;)
[1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one]
.
;)
Ondansetron hydrochloride having approximately 0.4% w/w of both ondansetron related compound A and 6,6¢-methylene bis-[(1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one)].
;)
.
;)
[(7,8-didehydro-oxandrolone) or (17;)
[(anhydro-oxandrolone) or (17;)
[anhydro-oxandrolone (17,17-dimethyl-2-oxa-18-nor-5;)
.
;)
.
;)
.
;)
.
;)
.
;)
(C14H18O3 ;)
[methyl ester of phenylcyclohexylglycolic acid, or CHMME (cyclohexyl mandelic acid methyl ester)]
.
;)
[methylethyl analog of oxybutynin chloride, or (4-(ethylmethylamino) but-2-ynyl (±) 2-cyclohexyl-2-hydroxy-2-phenylacetate hydrochloride)]
.
;)
.
;)
.
;)
.
;)
.
;)
.